Regulations.gov document
Determination That PEPCID (Famotidine) for Oral Suspension, 40 Milligrams/5 Milliliters…
Notice · FDA-2021-P-1111 · posted Apr 7, 2022
Key facts
| Document ID | FDA-2021-P-1111-0004 |
|---|---|
| Title | Determination That PEPCID (Famotidine) for Oral Suspension, 40 Milligrams/5 Milliliters, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness |
| Document type | Notice |
| Subtype | Determinations |
| Agency | FDA |
| Docket | FDA-2021-P-1111 |
| Posted | Apr 7, 2022 |
| Federal Register citation | 87 FR 20419 |
| FR document number | 2022-07391 |
| Comment period opens | Apr 7, 2022 |
| Effective date | Apr 7, 2022 |
At a glance
- 1–9 Pages
- None Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: